Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review
- PMID: 34052248
- DOI: 10.1016/j.diabres.2021.108871
Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review
Abstract
Background: Glycemic control and weight gain are two essential considerations in the pharmacological management of type 2 diabetes mellitus. Pharmacological agents are effective in lowering blood glucose levels but may result in significant weight gain. Liraglutideeffectively maintains glycemic control while reducingweight.
Methods: This is a real-world study and brief narrative review of the effects of liraglutide on glycemic control and weight in adult patients with type 2 diabetes mellitus. The study uses data extracted from the electronic health record of the Ministry of National Guard-Health Affairs.
Results: In this study of 348 subjects, there was a statistically significant reduction in hemoglobin A1c of 0.9% (P < .0001) and weight of 2.3 kg (P < .0001). The majority (77.3%) were on concomitant insulin.Subjects with a baseline hemoglobin A1c greater than 9% had a significantly greater reduction than those below 9% (-0.7%;P < .0001). Those with a weight more than 100 kg had a significantly greater reduction than those below 100 kg (-0.9 kg;P = .0096).
Conclusion: In this real-world, observational study, liraglutide was shown to be effective in improving glycemic control and reducing weight in adult patients with type 2 diabetes mellitus.
Keywords: Clinical outcomes; GLP-1 receptor agonist; Liraglutide; Ministry of National Guard-Health Affairs; Narrative review; Saudi Arabia.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.Clin Ther. 2015 Mar 1;37(3):574-84. doi: 10.1016/j.clinthera.2014.11.015. Epub 2015 Jan 24. Clin Ther. 2015. PMID: 25626486
-
Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.Clin Ther. 2016 Dec;38(12):2642-2651. doi: 10.1016/j.clinthera.2016.11.003. Epub 2016 Nov 23. Clin Ther. 2016. PMID: 27889301
-
Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.J Med Econ. 2016;19(4):403-13. doi: 10.3111/13696998.2015.1131703. Epub 2016 Jan 8. J Med Econ. 2016. PMID: 26653068
-
The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.Ann Pharmacother. 2018 Jan;52(1):69-77. doi: 10.1177/1060028017726348. Epub 2017 Aug 11. Ann Pharmacother. 2018. PMID: 28799414 Review.
-
Liraglutide for type 2 diabetes mellitus.Expert Opin Biol Ther. 2011 Jul;11(7):951-9. doi: 10.1517/14712598.2011.583641. Epub 2011 May 12. Expert Opin Biol Ther. 2011. PMID: 21563859 Review.
Cited by
-
Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.Mol Biol Rep. 2025 Jun 5;52(1):550. doi: 10.1007/s11033-025-10641-w. Mol Biol Rep. 2025. PMID: 40471368 Free PMC article. Review.
-
Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population.J Investig Med. 2024 Dec;72(8):911-919. doi: 10.1177/10815589241270427. Epub 2024 Aug 12. J Investig Med. 2024. PMID: 39075666 Free PMC article.
-
Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial.Diabetes Ther. 2023 Nov;14(11):1889-1902. doi: 10.1007/s13300-023-01462-w. Epub 2023 Sep 14. Diabetes Ther. 2023. PMID: 37707701 Free PMC article.
-
From hyperglycemia to intervertebral disc damage: exploring diabetic-induced disc degeneration.Front Immunol. 2024 Feb 20;15:1355503. doi: 10.3389/fimmu.2024.1355503. eCollection 2024. Front Immunol. 2024. PMID: 38444852 Free PMC article. Review.
-
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).Arch Endocrinol Metab. 2024 Nov 25;68:e240422. doi: 10.20945/2359-4292-2024-0422. eCollection 2024. Arch Endocrinol Metab. 2024. PMID: 39664998 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical